Jeremie Prevost
Overview
Explore the profile of Jeremie Prevost including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
2661
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Brunet-Ratnasingham E, Morin S, Randolph H, Labrecque M, Belair J, Lima-Barbosa R, et al.
Nat Commun
. 2024 May;
15(1):4177.
PMID: 38755196
Plasma RNAemia, delayed antibody responses and inflammation predict COVID-19 outcomes, but the mechanisms underlying these immunovirological patterns are poorly understood. We profile 782 longitudinal plasma samples from 318 hospitalized patients...
12.
Benlarbi M, Richard J, Bourassa C, Tolbert W, Chartrand-Lefebvre C, Gendron-Lepage G, et al.
J Infect Dis
. 2023 Nov;
229(3):763-774.
PMID: 38035854
Background: Chronic inflammation persists in some people living with human immunodeficiency virus (HIV) during antiretroviral therapy and is associated with premature aging. The glycoprotein 120 (gp120) subunit of HIV-1 envelope...
13.
Therrien C, Prevost J, Blais A, Turcotte S, Gendron-Lepage G, Finzi A, et al.
J Virol Methods
. 2023 Oct;
322:114836.
PMID: 37890729
No abstract available.
14.
Prevost J, Chen Y, Zhou F, Tolbert W, Gasser R, Medjahed H, et al.
Nat Commun
. 2023 Oct;
14(1):6710.
PMID: 37872202
The HIV-1 entry inhibitor temsavir prevents the viral receptor CD4 (cluster of differentiation 4) from interacting with the envelope glycoprotein (Env) and blocks its conformational changes. To do this, temsavir...
15.
Benlarbi M, Richard J, Bourassa C, Tolbert W, Chartrand-Lefebvre C, Gendron-Lepage G, et al.
medRxiv
. 2023 Aug;
PMID: 37645879
Background: Chronic inflammation persists in some people living with HIV (PLWH), even during antiretroviral therapy (ART) and is associated with premature aging. The gp120 subunit of the HIV-1 envelope glycoprotein...
16.
Marchitto L, Benlarbi M, Prevost J, Laumaea A, Descoteaux-Dinelle J, Medjahed H, et al.
mBio
. 2023 Jul;
14(4):e0078923.
PMID: 37404017
HIV-1 evades antibody-dependent cellular cytotoxicity (ADCC) responses not only by controlling Env conformation and quantity at the cell surface but also by altering NK cell activation via the downmodulation of...
17.
Prevost J, Chen Y, Zhou F, Tolbert W, Gasser R, Medjahed H, et al.
bioRxiv
. 2023 May;
PMID: 37131729
The HIV-1 entry inhibitor temsavir prevents CD4 from interacting with the envelope glycoprotein (Env) and blocks its conformational changes. To do this temsavir relies on the presence of a residue...
18.
Richard J, Prevost J, Bourassa C, Brassard N, Boutin M, Benlarbi M, et al.
Cell Chem Biol
. 2023 Mar;
30(5):540-552.e6.
PMID: 36958337
While HIV-1-mediated CD4 downregulation protects infected cells from antibody-dependent cellular cytotoxicity (ADCC), shed gp120 binds to CD4 on uninfected bystander CD4 T cells, sensitizing them to ADCC mediated by HIV...
19.
Laumaea A, Marchitto L, Ding S, Beaudoin-Bussieres G, Prevost J, Gasser R, et al.
Cell Rep
. 2023 Jan;
42(1):111983.
PMID: 36640355
HIV-1 envelope (Env) conformation determines the susceptibility of infected CD4 T cells to antibody-dependent cellular cytotoxicity (ADCC). Upon interaction with CD4, Env adopts more "open" conformations, exposing ADCC epitopes. HIV-1...
20.
Prevost J, Warner B, Safronetz D
Nat Microbiol
. 2023 Jan;
8(1):8-9.
PMID: 36604509
No abstract available.